MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study to evaluate various intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Principal trial targets have been To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis